HELSINKI, Finland, September 2022. Euformatics, a Finnish company providing services for NGS variant interpretation and quality control, had previously added Quimiolab S.A.S. to its channel partner network as their service distributors in Colombia. The relationship has proven fruitful with the inclusion of the clinical laboratory Alife Health as users of omnomicsNGS.

Last year, Euformatics set a goal to expand its partner network in Latin America, signing multiple agreements with different distributors for Colombia, Mexico, Peru, Bolivia and Paraguay. The expertise and knowledge of the local market of distributors, such as Quimiolab, being a key feature to facilitate the process of bringing the omnomics Suite to new frontiers. This reasoning has been proven correct with the most recent addition of Alife Health to the user base of omnomicsNGS.

Alife Health is a specialized Colombian clinical laboratory offering services for next-generation sequencing (NGS) for germline tests and somatic and liquid biopsies; as well as molecular biology test (PCR), HPV testing, and Flow Cytometry for the diagnosis of leukemias and lymphomas. Following a trial period exploring OmnomicsNGS and the Orchestrator, Alife decided to integrate our software options into their pipeline to support the variant calling and interpretation segments of their NGS services.

Quimiolab General Manager, Liliana Ramirez, commented: “We are glad to see our business relationship grow with the inclusion of Alife Health as a new user of Euformatics’ solutions for variant interpretation and secondary analysis. In the past, we explore Euformatics’ software and noticed the potential that it had to support and complement the bioinformatic pipelines of the local laboratories and hospitals. On that basis, we decided to collaborate as their distributors, and now we are glad to have introduced the laboratory Alife Health to Euformatics’ offering.”

Sequencing Scientific Director at Alife Health, Daniel Alzate, added: “We compared and evaluated different Bioinformatic solutions, concluding that the flexibility granted to create filtering strategies in OmnomicsNGS, complemented with the secondary analysis functionality, were the best suited for our current needs in the Sequencing Unit. We are optimistic to continue scaling our operations with confidence in the performance of the package offered by Euformatics. The Finland support team is always ready to provide support to all our needs as we integrate the new tools into our pipelines.”

The CEO of Euformatics, Tommi Kaasalainen, concluded: “The integration of Alife Health to our user base has been the result of a collaborative effort between the teams of Euformatics and Quimiolab to ensure that all the laboratory needs were addressed during the trial period and following negotiations. Naturally, this milestone wouldn’t have been possible without the expertise and support of our distributor partner. Quimiolab has hit the bullseye, matching our NGS solutions to the needs of the clinical laboratory in their native Colombia. We will continue to look forward with our goal of accelerating the transition to precision medicine beyond new borders.”

The Finnish summer has come to an end, and we are glad to have met this milestone as we gear up for a new set of challenges. We hope to continue increasing our presence in the American continent as we join the annual meeting of the American Society of Human Genetics in Los Angeles this October, find out more about it in our website and social media soon enough.

About Quimiolab:

At Quimiolab improving the health of Colombians is in our DNA, the company that has had the main purpose of becoming a strategic ally for medium and high-complexity laboratories in Colombia. A strong customer-focused approach and the constant quest for high-quality products have enabled the company to sustain leadership in its major lines of business for 25 years. Our main goal is to support diagnostic procedures with specialized tests for autoimmunity, metabolic, infectious, and genetic diseases. Currently, we have surrounded ourselves with an incredible multidisciplinary team who, from their scientific perspectives, assist the improvement of diagnostics of each laboratory. 

For more information, please visit our website

About Alife Health:

The Alife Health Laboratory is an institution that focuses on a high-quality complex diagnosis. Our differential character is ethics, scientific rigor, clinical support, and opportune time. Our services include the processing of molecular tests by PCR (SARS-COV-2, Human Papilloma Virus, Tumor Markers). Flow Cytometry (Diagnosis of Leukemias and lymphomas, HIV, among others). Next Generation Genetic Sequencing NGS (Whole Exomes, Clinical Exomes, Hereditary Cancer Panel, Molecular Profiling of Solid Tumors, Liquid Biopsy) and Routine Clinical Examination services.

For more information, please visit our website

About Euformatics:

Euformatics is a Finnish software company that specializes in high-standard bioinformatics tools for genomic data interpretation. Since 2010, Euformatics has been helping medical doctors and molecular genetics laboratories provide better precision medicine for cancer, common or rare disease diagnostics. At present, our core solution is the omnomics Suite which includes omnomicsNGS; for clinical analysis and reporting of patient NGS data, and omnomicsQ; for NGS data quality management.

For more information, please visit our website

Press Relations:

Tommi Kaasalainen

Back to news listing